AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01831440 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: medicine combined CBT
Description: medicine：Clinical routine antidepressant treatment CBT：During the treatment period，weekly for 8 weeks，and monthly for the maintenance phase.Therapists receive group supervision monthly.
Study NCT01831440 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: medicine
Description: Participants receive only clinical routine antidepressant treatment,Which include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.
Study NCT01143896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Depression collaborative care model
Description: The intervention will include a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.
Study NCT04000334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAP increased to optimize cerebral blood flow
Description: MAP will be increased to 90-100 mmHg with norepinephrine. If TCD is still abnormal with a MAP of 90-100 mmHg, MAP will be increased to 100-110 mmHg. At each step, all CBF determinants will be recorded as well as cardiac output and Veinous jugular oxygen saturation (SvjO2). When TCD is normalized with no complications, MAP will be maintained at 90-100 or 100-110 mmHg during 24 hours.
Study NCT04000334 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MAP between 65 and 85 mmHg
Description: MAP will be maintained between 65-85 mmHg, using a norepinephrine infusion as needed.
Study NCT02179255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Growth Hormone
Description: 1.9 mg (5.7 units) daily injection of Recombinant Human Growth Hormone (HGH) for at least 6 weeks (42 days) continuing into the approximately 14 days of ovulation induction phase of the trial.
Study NCT02179255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follicle Stimulating Hormone
Description: FSH 450 to 600 units per day administered SQ daily dose adjusted based on the patients response starting on day 2 of the 28 day menstrual cycle and continued until Ovulation trigger
Study NCT02179255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follicle Stimulating Hormone
Description: FSH 450 to 600 units per day administered SQ daily dose adjusted based on the patients response starting on day 2 of the 28 day menstrual cycle and continued until Ovulation trigger
Study NCT01318070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and pioglitazone
Description: Alogliptin 12.5mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
Study NCT01318070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and pioglitazone
Description: Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
Study NCT01318070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
Study NCT01592019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference, Patch location thigh, batch 1
Description: Reference, Patch location thigh, batch 1
Study NCT01592019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test, Patch location thigh, batch 2
Description: Test, Patch location thigh, batch 2. Three probes will be inserted at each visit.
Study NCT01592019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference, Patch location abdomen, batch 1
Description: Reference, Patch location abdomen, batch 1
Study NCT01592019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test, Patch location abdomen, batch 2
Description: Test, Patch location abdomen, batch 2. Three probes will be inserted at each visit.
Study NCT01352637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DCS (D-Cycloserine ) + Prolonged Imaginal Exposure
Description: 50mg DCS (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure
Study NCT01352637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DCS (D-Cycloserine ) + Virtual Reality Exposure
Description: 50mg DCS (taken once a week on the day of the therapy session) + Virtual Reality Exposure
Study NCT01352637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Prolonged Imaginal Exposure
Description: Placebo (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure
Study NCT01352637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sugar pill) + Virtual Reality Exposure
Description: Placebo (taken once a week on the day of the therapy session) + Virtual Reality Exposure
Study NCT00913393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-3019
Description: 3 mg/kg FG-3019 IV every 2 weeks for 22 weeks
Study NCT00913393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-3019
Description: 10 mg/kg FG-3019 IV every 2 weeks for 22 weeks
Study NCT00913393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV every 2 weeks for 22 weeks
Study NCT01920152 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: Each PRP preparation requires a total of 36 ml of peripheral blood. This will be obtained via venapuncture and collected in four 9 ml extraction tubes containing 3.8% sodium citrate. The tubes are then centrifuged at 640 rpm for 8 minutes at room temperature. The 1ml plasma fraction located above the buffy coat is aspirated from each tube and dispensed into the fractioning tube. The entire PRP process takes place under laminar airflow. Immediately prior to injection, calcium chloride is is drawn up from the activator ampoule with the activation syringe and is added to the PRP fractioning tube. The activated PRP is then injected in its entirety into the hip joint under strict aseptic technique.
Study NCT01920152 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: Hyaluronic acid is supplied as a non-pyrogenic solution in 2.5 ml pre-filled syringes and is administered by intra-articular injection using a 22-23 gauge needle. The full 2.5 ml is injected in one joint under strict aseptic administration.
Study NCT01350115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDE225
Description: supplied as 100 mg capsules
Study NCT01350115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: supplied in capsules
Study NCT03916016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Integrated Behavioral Health Care
Description: The intervention involved moving from HFHC's previous collaborative model, where medical and behavioral providers worked with each other episodically, to a more fully integrated collaborative care model with care coordination, shared treatment plans, shared service provision, and shared record keeping. To achieve this enhanced level of integration, HFHC changed its current primary care workflow to include a behavioral health specialist who conducted assessments, provided initial counseling (individual or group), and coordinated referrals to care management and/or community-based health services.
Study NCT03916016 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: A collaborative model where medical and behavioral providers worked with each other episodically
Study NCT00641342 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: onlay mesh
Description: StomaMesh (Precut heavyweight polypropylene mesh) Vypro Mesh (lightweight Prolene and vicryl mesh)
Study NCT02275728 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training
Description: assessment and intervention group with a training of the pelvic floor muscles, another group with training of the pelvic floor muscles and electromyographic biofeedback and a control group will be held. All groups respond to a questionnaire of quality of life. At the end, all groups will be reassessed and compare the effectiveness of interventions between groups.
Study NCT02275728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Description: assessment and intervention group with a training of the pelvic floor muscles, another group with training of the pelvic floor muscles and electromyographic biofeedback and a control group will be held. All groups respond to a questionnaire of quality of life. At the end, all groups will be reassessed and compare the effectiveness of interventions between groups.
Study NCT02275728 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eletromyography Biofeedback
Study NCT04035096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: 1. Start with IVC (intravenous ascorbic acid) 25 g biweekly, 50 g biweekly, and 75 g biweekly. If the target blood level is below 350mg/dl, the dose will titrate up to 100 g/dose or maximal dose of 1.5g/kg/dose to achieve the target level.~2. The final dose will be kept for 12 weeks.~3. Maintenance dose: 75-100g every 2 week will be maintained for additional 12 weeks
Study NCT04035096 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: 1. Selection of control group: stage IV colon cancer patients match for sex, age and chemotherapy /target therapy drugs~2. Usual care
Study NCT00784732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAV680
Study NCT00784732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate
Study NCT05805748 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: serious game rehabilitation
Description: The SG rehabilitation was proposed to be played four times per week for three weeks, for a total of 12 sessions, with 15 min per session (= 60 minutes per week). Conventional rehabilitation comprised five sessions of 45 min of neuropsychological rehabilitation using classical exploration training (= 225 minutes per week).
Study NCT04041427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole Pill
Description: Albendazole 400mg po
Study NCT04041427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat content diet
Description: High fat content diet
Study NCT04041427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate fat content die
Description: Moderate fat content die
Study NCT01077180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of the Rheos System
Description: Open label
Study NCT02496832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluoroazomycin arabinoside
Study NCT03402685 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearSight
Description: Patients in the intervention group receive management of volume and vasopressor settings according to the non-invasive ClearSight system.
Study NCT00417807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesilate
Study NCT01077180 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care medical management
Description: Patients will continue with medical therapy for standard of care of their hypertension.
Study NCT04292990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Patch releasing drug at the rate of 25 µg/hour, increasing by 25 µg/hour increments to maintain the NRS score≤3 after the frst 24 hours according to no change in pain control. The maximum dose allowed in this study is 300 µg/hour.
Study NCT04292990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Tablets taken orally, twice daily, morning \& evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: starting at 30 mg, increasing at a minimum of 3 days intervals by 20 mg, with a maximum dose of 100 mg. Maintenance phase: continuing on dose level established in titration phase.
Study NCT00378898 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BRAVO capsule
Study NCT00378898 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy
Description: one time xray to determine evacuation of bravo
Study NCT00378898 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham BRAVO capsule placement
Study NCT03456856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Film-coated tablets taken orally with food twice a day. Tablets supplied in strengths of 5.0 mg and 7.5 mg. 5.0 tablets were split into equal halves for dosages of 2.5 mg.
Study NCT00476294 — intervention group
Intervention type: OTHER
Intervention: Telephone Questionnaire
Description: Follow-Up Telephone Calls Every 6 Months for 5 Years.
Study NCT03510871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab, ipilimumab
Description: All enrolled subjects will receive nivolumab 3 mg/kg plus ipilimumab 1 mg/kg intravenously on day 1 of each cycle (every 3 weeks). Tumor assessment will be done after 6 weeks (2 cycles) and 12 weeks (4 cycles).
Study NCT05270226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Metacognitive ADHD Telehealth intervention for Work-performance Enhancement (Work-MATE)
Description: The Metacognitive ADHD Telehealth intervention for Work-performance Enhancement (Work-MATE) is an innovative program that aim to improve occupational performance at work of adults with ADHD, by enhancing their EF abilities, self-awareness, and personal strategy use.~The Work-MATE is a short, synchronous and hybrid teleintervention program of eleven 1-hour weekly individual sessions. It offers a written standardized protocol, which include uniform structure of each intervention session and pool of therapy aids (for self-tailored matching by occupational therapists).
Study NCT02680210 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires and cognitive measures
Study NCT03897218 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oatmeal flakes with prebiotic food supplements
Description: The study participants should consume the prescribed amount of the study product every day. The intake should be divided into 1-2 meals. It is not necessary to limit or change normal eating habits.
Study NCT02943876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: personalized depression risk information
Description: The personalized depression risk information is determined by sex-specific risk prediction algorithms based on one's family history of depression, current health status, childhood traumatic experience and ongoing life stressors. The information is in the form of probability of having a major depressive episode in the next 4 years.
Study NCT03897218 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: millet flakes
Description: The study participants should consume the prescribed amount of the study product every day. The intake should be divided into 1-2 meals. It is not necessary to limit or change normal eating habits.
Study NCT01474382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OraVerse
Description: 1.8mL dental cartridge delivered in doses of either 1/4, 1/2 or 1 cartridge depending on subject weight
Study NCT01474382 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: No drug administered, simulation of injection used in same manner as drug
Study NCT01643876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palatal brushing
Description: Participants will be instructed to brush their palate with a manual soft-bristle brush after each meal and before sleeping for a period of 3 months. They will be asked to keep to their usual oral and denture hygiene routine during the trial to allow the isolation of the effect of palatal brushing.
Study NCT04739397 — intervention group
Intervention type: DEVICE
Intervention: Glare Testing
Description: Vision in Cataract patients were tested with and without the EpiGlare Tester
Study NCT02525913 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RFA Applicator
Study NCT01995552 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: External Loop Recorder
Study NCT01665989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Lifestyle Program
Study NCT03580317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EA+ Carbamazepine
Description: Acupoints selection: Si-bai(ST2), Xia-guan(ST7), Di-cang(ST4), Quan-liao(SI18), Jia-che(ST6) and A-shi-xue of affected side. He-gu(LI4) and Wai-guan(TE5) of two sides.~Operation:The needles(0.18×25 mm) will be selected to stimulate the local points with shallow row needling according to the distribution of neuropathy branch of trigeminal neuralgia.The needles(0.25×40mm) will be selected to stimulate the distal acupoints. The Xia-guan(ST7) and Quan-liao(SL18) (or Jia-che(ST6)), He-gu(LI4) and Wai-guan(SJ5) acupoints will be received EA treatment by HuaTuo SDZ-ⅡB acupoint neural stimulator. The EA parameter is 2/100 Hz, 60 minutes and the current intensity is comfortable to subjects. Carbamazepine tablets should be took orally, 0.1g each time, thrice daily.
Study NCT03580317 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: EA+Placebo
Description: In this group, the selection, positioning and manipulation of acupoints, the frequency, duration and retaining needle time of treatment are same as EA + Carbamazepine Group; placebo, that appearance and specifications are the same as carbamazepine, are cooperated taken of dose 0.1g, thrice daily.
Study NCT01976494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The domestic PCA equipment 'Accufuser Omnibus®'
Description: * Subject patient selection: the purpose and method of this research will be explained to the patients who satisfy the exclusion criteria before surgery, and written consent regarding research participation will be obtained.~* Use of PCA equipment by patients is determined by randomization. Regardless of the PCA equipment type, the basal rate and bolus dose are equally set to 2 mL/hr and 2 mL for the entire research period.~* Epidural PCA regime: normal saline added to 0.75% ropivacaine 40 mL and fentanyl 15-20 mcg/kg for a total volume of 100 ml.~* After pretreatment, the chest epidural catheter is mounted in the pretreatment room or operating room. The catheter tip is adjusted to be fixed between T6-7 or T7-8.~* After mounting the catheter, a test dose of 1% lidocaine 3 ml and epinephrine 1:200.000 is injected. Ten minutes later, sensory loss and skin dermatome will be checked using an alcohol swab.
Study NCT01976494 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Imported PCA equipment 'Infusor SV®, Baxter, USA'
Description: * Subject patient selection: the purpose and method of this research will be explained to the patients who satisfy the exclusion criteria before surgery, and written consent regarding research participation will be obtained.~* Use of PCA equipment by patients is determined by randomization. Regardless of the PCA equipment type, the basal rate and bolus dose are equally set to 2 mL/hr and 2 mL for the entire research period.~* Epidural PCA regime: normal saline added to 0.75% ropivacaine 40 mL and fentanyl 15-20 mcg/kg for a total volume of 100 ml.~* After pretreatment, the chest epidural catheter is mounted in the pretreatment room or operating room. The catheter tip is adjusted to be fixed between T6-7 or T7-8.~* After mounting the catheter, a test dose of 1% lidocaine 3 ml and epinephrine 1:200.000 is injected. Ten minutes later, sensory loss and skin dermatome will be checked using an alcohol swab.
Study NCT03725904 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Progesterone analysis in saliva
Description: Analysis of salava progesterone
Study NCT03318822 — intervention group
Intervention type: DEVICE
Intervention: Q-Collar
Description: An externally-worn medical device that applies mild jugular compression
Study NCT03820518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Study NCT01896596 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menjugate
Description: Administered with routine vaccinations at 3 months of age
Study NCT01896596 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menitorix
Description: Administered with routine vaccinations at 3 months
Study NCT01896596 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NeisVac-C
Description: Administered with routine vaccinations at 3 months
Study NCT01909635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Feelings
Study NCT01909635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Other Feelings
Study NCT04060706 — intervention group
Intervention type: RADIATION
Intervention: Radical Image-Guided Radiotherapy
Description: Questionnaires administered will monitor the clinical toxicity experienced by each patient up to 5 years post radiotherapy
Study NCT03316599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.